Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
9 drugs in development
By Therapeutic Area
top 3
R&D Momentum
92/100
Pipeline Velocity
70/100
Trial Completion Rate
67/100
Pipeline Concentration
28/100
Pipeline Freshness
74/100
Strategic Signals
Activity
Last 14 days
Bridging Maternal Lifestyle Education, and Counseling With Community Health Workers and Health Equity - Phase II
An Evaluation Of Home Urinalysis Testing For Systemic Lupus Erythematosus (SLE) Patients At Elevated Risk For Developing Lupus Nephritis: A Pilot Stage And Randomized, Controlled Study
Targeting Reward Circuits: Psilocybin as a Novel Therapy for Residual Anhedonia
LINK-IT: Leveraging vIdeos and commuNity Health worKers to Improve Diabetes OuTcomes
Effectiveness and Implementation of an Early Childhood School-Based Mental Health Intervention in Low-Resource Communities
Communication Compass Feedback
Earlier
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)